{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:47:15Z","timestamp":1782874035181,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"DOI":"10.1186\/s13104-026-07848-w","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:52:57Z","timestamp":1778233977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timeliness of switching to second-line antiretroviral therapy following virologic failure in Dar es Salaam, Tanzania"],"prefix":"10.1186","volume":"19","author":[{"given":"Majid Hussein","family":"Thadeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Msema","family":"Bwire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"7848_CR1","unstructured":"The United Republic of Tanzania. UNAIDS report 2024. https:\/\/www.unaids.org\/en\/regionscountries\/countries\/unitedrepublicoftanzania. Accessed 25 Sept 2025."},{"key":"7848_CR2","unstructured":"National Bureau of Statistics. Tanzania HIV impact survey 2022\u20132023. https:\/\/www.nbs.go.tz\/index.php\/en\/census-surveys\/health-statistics\/hiv-and-malaria-survey\/932-the-tanzania-hiv-impact-survey-2022-2023-summary-sheet. Accessed 01 Feb 2024."},{"key":"7848_CR3","unstructured":"National AIDS Control Programme. The United Republic of Tanzania, HIV treatment guideline; 2019. https:\/\/differentiatedservicedelivery.org\/wp-content\/uploads\/national_guidelines_for_the_management_of_hiv_and_aids_2019.pdf. Accessed 03 Mar 2023."},{"key":"7848_CR4","unstructured":"Consolidated guidelines on HIV. viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. https:\/\/www.who.int\/publications\/i\/item\/9789240052390. Accessed 09 May 2024."},{"key":"7848_CR5","unstructured":"World Health Organization HIV drug resistance early warning indicators. https:\/\/www.who.int\/publications\/i\/item\/9789241503945. Accessed 20 Nov 2023."},{"key":"7848_CR6","unstructured":"WHO. What\u2019s new in treatment monitoring: viral load and CD4 testing. HIV treatment and care information note; 2017. p. 1\u20132."},{"issue":"1","key":"7848_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12879-023-08155-6","volume":"23","author":"D Mnzava","year":"2023","unstructured":"Mnzava D, et al Decentralization of viral load testing to improve HIV care and treatment cascade in rural Tanzania: observational study from the Kilombero and Ulanga Antiretroviral Cohort. BMC Infect Dis. 2023;23(1):222. . https:\/\/doi.org\/10.1186\/s12879-023-08155-6.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"7848_CR8","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1186\/s12889-022-13504-2","volume":"22","author":"MD Pham","year":"2022","unstructured":"Pham MD, Nguyen HV, Anderson D, Crowe S, Luchters S Viral load monitoring for people living with HIV in the era of test and treat: progress made and challenges ahead\u2014a systematic review. BMC Public Health. 2022;22(1):1203. . https:\/\/doi.org\/10.1186\/s12889-022-13504-2.","journal-title":"BMC Public Health"},{"issue":"1","key":"7848_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1186\/s12879-017-2680-6","volume":"17","author":"V Ssempijja","year":"2017","unstructured":"Ssempijja V, et al Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda. BMC Infect Dis. 2017;17(1):582. https:\/\/doi.org\/10.1186\/s12879-017-2680-6.","journal-title":"BMC Infect Dis"},{"key":"7848_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47795-1","author":"GM Bwire","year":"2023","unstructured":"Bwire GM, et al High viral suppression and detection of dolutegravir-resistance associated mutations in treatment-experienced Tanzanian adults living with HIV-1 in Dar es Salaam. Sci Rep. 2023. https:\/\/doi.org\/10.1038\/s41598-023-47795-1.","journal-title":"Sci Rep"},{"key":"7848_CR11","unstructured":"Organization WH. HIV drug resistance early warning indicators data abstraction and analysis tools. http:\/\/www.who.int\/hiv\/drugresistance\/. Accessed 19 Mar 2023."},{"key":"7848_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijid.2020.02.031","volume":"95","author":"Y Getaneh","year":"2020","unstructured":"Getaneh Y, et al HIV drug resistance early warning indicators in Ethiopia: variability at regional and health facility levels and trend over time. Int J Infect Dis. 2020;95:90\u20137. https:\/\/doi.org\/10.1016\/j.ijid.2020.02.031.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"7848_CR13","doi-asserted-by":"publisher","first-page":"e0000929","DOI":"10.1371\/journal.pgph.0000929","volume":"3","author":"SA Khamadi","year":"2023","unstructured":"Khamadi SA, Mavere C, Bahemana E, Lwilla A, Mizinduko M, Bwigane S. Early warning indicators of HIV drug resistance in the southern highlands region of Tanzania: lessons from a cross-sectional surveillance study. PLOS Glob Public Health. 2023;3(3):e0000929. https:\/\/doi.org\/10.1371\/journal.pgph.0000929.","journal-title":"PLOS Glob Public Health"},{"issue":"12","key":"7848_CR14","doi-asserted-by":"publisher","first-page":"e82724","DOI":"10.1371\/journal.pone.0082724","volume":"8","author":"Y Madec","year":"2013","unstructured":"Madec Y, Leroy S, Rey-Cuille M-A, Huber F, Calmy A Persistent difficulties in switching to second-line ART in sub-Saharan Africa\u2014a systematic review and meta-analysis. PLoS ONE. 2013;8(12):e82724. https:\/\/doi.org\/10.1371\/journal.pone.0082724.","journal-title":"PLoS ONE"},{"issue":"6","key":"7848_CR15","doi-asserted-by":"publisher","first-page":"e080434","DOI":"10.1136\/bmjopen-2023-080434","volume":"14","author":"N Machumu","year":"2024","unstructured":"Machumu N, Frumence G, Anaeli A. Facilitators and barriers to optimum uptake of multimonth dispensing of antiretroviral treatment in Morogoro, Tanzania: a qualitative study. BMJ Open. 2024;14(6):e080434. https:\/\/doi.org\/10.1136\/bmjopen-2023-080434","journal-title":"BMJ Open"},{"key":"7848_CR16","unstructured":"Mgosha PC. Barriers to switching patients to second-line antiretroviral treatment among clinicians in Tanzania. https:\/\/scholarworks.waldenu.edu\/dissertations\/3535\/?utm. Accessed 02 Oct 2025."},{"key":"7848_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/v15091932","volume-title":"Treatment emergent Dolutegravir resistance mutations in individuals na\u00efve to HIV-1 integrase inhibitors: a rapid scoping review","author":"K Tao","year":"2023","unstructured":"Tao K, et al. Treatment emergent Dolutegravir resistance mutations in individuals na\u00efve to HIV-1 integrase inhibitors: a rapid scoping review. Multidisciplinary Digital Publishing Institute (MDPI); 2023. https:\/\/doi.org\/10.3390\/v15091932"},{"key":"7848_CR18","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1093\/jac\/dkz256","volume":"74","author":"S Rhee","year":"2019","unstructured":"Rhee S, et al. A systematic review of the genetic mechanisms of dolutegravir resistance. J Antimicrob Chemother. 2019;74:3135\u201349. https:\/\/doi.org\/10.1093\/jac\/dkz256.","journal-title":"J Antimicrob Chemother"},{"key":"7848_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/v16030399","volume-title":"Prevalence of emergent Dolutegravir resistance mutations in people living with HIV: a rapid scoping review","author":"C Chu","year":"2024","unstructured":"Chu C, et al. Prevalence of emergent Dolutegravir resistance mutations in people living with HIV: a rapid scoping review. Multidisciplinary Digital Publishing Institute (MDPI); 2024. https:\/\/doi.org\/10.3390\/v16030399"},{"key":"7848_CR20","doi-asserted-by":"publisher","unstructured":"Loosli T, et al. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. Lancet HIV. Nov. 2023;10(11):e733\u201341. https:\/\/doi.org\/10.1016\/S2352-3018(23)00228-X.","DOI":"10.1016\/S2352-3018(23)00228-X"},{"issue":"10","key":"7848_CR21","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1093\/jac\/dkz272","volume":"74","author":"G Barabona","year":"2019","unstructured":"Barabona G, et al. Pre-Treatment and acquired HIV drug resistance in Dar es Salaam, Tanzania in the era of tenofovir and routine viral load monitoring. J Antimicrob Chemother. 2019;74(10):3016\u201320. https:\/\/doi.org\/10.1093\/jac\/dkz272.","journal-title":"J Antimicrob Chemother"},{"key":"7848_CR22","doi-asserted-by":"publisher","unstructured":"Kouamou V, Inzaule S, Manasa J. Dolutegravir drug-resistance monitoring in Africa, Nov. 01, 2021, Elsevier Ltd. https:\/\/doi.org\/10.1016\/S2352-3018(21)00268-X","DOI":"10.1016\/S2352-3018(21)00268-X"},{"key":"7848_CR23","doi-asserted-by":"publisher","unstructured":"Kouamou V, Inzaule S, Manasa J. Dolutegravir drug-resistance monitoring in Africa. Lancet HIV. Nov. 2021;8(11):e664\u20136. https:\/\/doi.org\/10.1016\/S2352-3018(21)00268-X.","DOI":"10.1016\/S2352-3018(21)00268-X"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-026-07848-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07848-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07848-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:30:27Z","timestamp":1782873027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13104-026-07848-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7848"],"URL":"https:\/\/doi.org\/10.1186\/s13104-026-07848-w","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained from the Muhimbili University of Health and Allied Sciences (MUHAS) Research and Ethics Committee (Ref. No. DA282\/298\/02L\/508). Additional permission to conduct the study was granted by Muhimbili National Hospital, the Regional Administration and Local Government of Ilala District, and the Office of the District Medical Officer. This study was conducted in accordance with the Declaration of Helsinki and all applicable national research ethics guidelines. Because the study used secondary data (retrospective design) extracted from routine hospital records, informed consent from individual participants was not required. The MUHAS Research and Ethics Committee reviewed and approved the waiver of informed consent. Strict measures were implemented to ensure privacy, confidentiality, and secure handling of patient information. All data were de-identified prior to analysis, and no personal identifiers were included in any reports, presentations, or publications.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}